INTRODUCTION
Induction chemotherapy (IC) remains a contentious aspect of management for locally advanced head and neck squamous cell carcinoma (HNSCC). To date, four phase III randomised controlled trials have investigated the role of IC prior to chemoradiotherapy for locally advanced HNSCC. Only one study showed an overall survival benefit (1).
Nevertheless, it is noteworthy that the negative studies had limitations with poor accrual, inadequate power and low radiotherapy completion rates (2-4).
Despite contradictory evidence regarding its overall survival benefit, IC remains a standard-of-care in organ sparing approaches in laryngeal cancer and appears to reduce distant failure rates in HNSCC (5, 6) . Good response to IC has been reported to be predictive of complete response to subsequent radiotherapy and long-term disease control (7, 8) . This concept has led to randomised clinical trials such as ECOG-1308 and Quarterback, which are investigating radiotherapy dose reduction in human papillomavirus (HPV)-driven stage III-IV oropharyngeal cancer using complete response to IC as a selection criterion (9). Conversely, patients with poor response to IC are at a higher risk of radiotherapy failure and require treatment intensification. Despite being an attractive strategy, IC is associated with increased rates of complications (10).
Therefore, an early predictive biomarker is essential to identify those who will or will not benefit.
Functional and molecular imaging (FMI) characterise the tumour phenotype by providing quantitiative information on biological processes such as metabolic activity, vascularity and cellularity (11). Biological changes measured by FMI are usually evident before morphological changes (12) and this confers a potential advantage over conventional imaging for early response assessment. Several studies have identified by on September 8, 2017. For personal use only. jnm.snmjournals.org Downloaded from biomarkers for HNSCC (13) (14) (15) (16) , with different, but complementary, biological information from each modality (17) . The majority of FMI studies are largely based on post-IC imaging but an earlier time-point for assessment during IC is required to allow time for an individualized treatment plan based on tumour response to therapy.
To address these issues, we established a prospective multimodality longitudinal FMI study (INSIGHT) in locally advanced HNSCC scheduled for radical chemoradiotherapy (18) . Here, we report the results of serial 18 
MATERIALS AND METHODS

Study Design
Patients were recruited at The Royal Marsden Hospital between July 2013 and 
PET/CT Image Acquisition
PET/CT studies were acquired using Phillips Gemini (London) and Siemens mCT (Sutton) PET/CT scanners. Patients were fasted for 6 hours before the study. 18F-FDG (400 MBq) was injected intravenously if the blood sugar level was <10 mmol/L. Prior to PET acquisition, patients rested for 60 minutes. Patients were positioned on a flat-top couch in their radiotherapy treatment position, using a headrest and 5-point thermoplastic shell. Emission data were acquired from the base of skull to carina (3 min/bed; average 2 bed acquisition). Unenhanced, low dose CT was performed from the base of skull to carina for purposes of attenuation correction and image fusion for anatomical localisation (approximate mAs 50/slice). 
Image Analysis
All PET and MRI data were analyzed using RayStation (version 4.6.1, RaySearch Medical Laboratories, AB Stockholm, Sweden), a radiotherapy treatment planning system. RayStation (internally validated for data accuracy) was chosen for its ability to handle large longitudinal multimodality image sets and incorporate radiotherapy dosimetry. Regions of interest (ROIs) encompassing the primary tumor (PT) or involved lymph nodes (LNs) were delineated on each imaging modality by a radiation oncologist. These contours were verified by experienced consultants in nuclear medicine (WO) and radiology (AR).
PET images reconstructed using ordered subset expectation maximisation were used for analysis. Two methodologies were used to generate the metabolic tumour volume (MTV): relative threshold of 40% of maximum standardised uptake volume (SUVmax) (MTV 40% ) and fixed threshold of SUV3.5 (MTV 3.5 ). The baseline value served as the threshold for MTV on subsequent scans. Other PET parameters including by on September 8, 2017. For personal use only. jnm.snmjournals.org Downloaded from SUVmax and total lesion glycolysis (TLG = SUVmean x MTV) (19) , were recorded for all ROIs at each time-point.
Anatomical contours for MRI were delineated on T 2 -weighted images with reference to T 1 -weighted images. For DW analysis, ROIs were defined on the T 2 -weighted low b-value images (b50) with reference to the co-registered anatomical contours, excluding regions of necrosis and cysts (Fig. 1 ). This accounts for potential local deformation of DW images in the vicinity of air-tissue interfaces and dental objects.
All b values were used to calculate the apparent diffusion coefficient (ADC). Due to the skewed distribution of ADC values, the median value was chosen as the statistical representation for individual ROI. ADC was recorded separately for PT and LNs.
The radiotherapy planning CT and dosimetry were imported to enable dosimetric analysis. Good co-registrations between FMI images and planning CT were achieved due to immobilisation, allowing rigid transformation of contours across all images.
Statistical Analysis
The data were analysed using SPSS statistical software (Version 21.0; IBM Corp, Armonk, NY). Depending on the normality of the data distribution (using Kolmogorov-Smirnov test), the changes in PET and DW-MRI parameters from baseline were compared between IC1 and IC2 using paired t-test (normal) or Wilcoxon signedrank test (non-normal). Changes in FMI parameters changes following IC1 were compared between responders and non-responders using the Mann-Whitney U test. The significance threshold was set at p<0.05. Receiver operator characteristics (ROC) analysis was used to identify and determine the optimal threshold values for parameters with predictive value.
Clinical Characteristics
Patient and treatment characteristics are shown in Table 1 . Seventeen out of 20 patients underwent 2 cycles of IC; three patients stopped IC after 1 cycle due to poor tolerance. One patient did not receive concomitant chemotherapy due to persistent myelosuppression following IC. All patients completed chemoradiotherapy within 42
days. Median follow-up was 14 (range 7-25) months.
Treatment Outcome
There were 15 responders and 5 non-responders. One responder underwent a modified radical neck dissection due to equivocal radiological appearance postchemoradiotherapy, but no viable residual disease was found. At the time of analysis, all responders remained alive and disease-free. All five non-responders had locoregional failure: two also developed distant metastases. Only one patient was deemed suitable for salvage surgery and underwent radical pharyngolaryngectomy. He remains diseasefree to date. The remaining four non-responders had died by the time of analysis (5-9 months post-chemoradiotherapy).
FMI -Responders Versus Non-responders
Baseline MTV 40%, MTV 3.5, TLG 40% and TLG 3.5 differed significantly between the two groups, but not for SUVmax and SUVmean (Table 2) . Responders also showed a significantly greater mean reduction in MTV 3.5 , TLG 3.5 and TLG 40% post-IC1 than nonresponders. The reductions in SUVmax and SUVmean were not discriminative between the two groups post-IC1 but did reach statistical significance post-IC2 (p=0.01 and 0.037, respectively). There was a clear association between MTV or TLG response and HPV status (Fig. 2) .
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There was no significant difference in pre-treatment ADC for both PT and LNs between the two groups ( Table 2 ). For patients with discernible tumour following IC1, the mean ADC for PT was higher in responders than non-responders but this did not reach statistical significance (p=0.089). LNs in responders also showed a greater, but statistically non-significant, increase in ADC post-IC1 than non-responders. The changes in ADC post-IC2 remained non-discriminative between responders and non-responders for both PT (p=0.343) and LNs (p=0.658). The pre-treatment mean ADC was significantly lower in the LNs for HPV-positive in comparison to HPV-negative HNSCC (0.95±0.13 vs.
1.07±0.15 x10 -3 mm 2 /s, p=0.025), but no difference was observed in the PT (1.15±0.18 vs. 1.16±0.14 x10 -3 mm 2 /s, p=0.93). Cumulatively, a tendency towards a larger increase in ADC post-IC1 was observed in HPV-positive tumours (Fig. 2) .
T stage (T1-2 vs. T3-4), N stage (N0-1 vs. N2-3) and tumour grade (G1-2 vs. G3) were all non-predictive of response to chemoradiotherapy (p>0.05). ROC analyses identified TLG 40% as the optimal predictive parameter for treatment response using relative threshold and MTV 3.5 using fixed threshold. A combination of pre-treatment TLG 40% <300 g and TLG 40% reduction >60% post-IC1 gave an improved sensitivity and specificity of 93% and 80% in predicting complete remission in comparison to individual parameters (Fig. 3) . A combination of MTV 3.5 <50 cm 3 and MTV 3.5 reduction >55% post-IC1 yielded similar result.
Longitudinal FMI Parameters
The longitudinal changes in 18 F-FDG-PET/CT and DW-MRI parameters during IC are summarised in Table 3 . In 17 evaluable patients, there was no significant difference in the changes from baseline between IC1 and IC2 for all PET parameters. This indicates that most metabolic response or non-response to IC was evident soon after
IC1
, with no significant change following a subsequent cycle. This remains the case after dichotomising the data to PT and LNs (Supplemental Table 1 ). However, it is noteworthy that the differences in SUVmax and SUVmean approached statistical significance (p=0.065 and 0.071, respectively).
Similarly, there was no significant difference in the magnitude of ADC changes between IC1 and IC2. Overall, the dominant trend of ADC observed for both PT and LNs was an increase. As anticipated, there was a significant difference in the anatomical changes for both PT and LNs between IC1 and IC2, with notable additional change after IC2, reaffirming that morphological change in HNSCC following IC lags behind biological change.
Radiotherapy Dosimetry
Review of the radiotherapy dosimetry in the non-responders (in relation to the 
DISCUSSION
We evaluated early assessment after IC1 using 18 F-FDG-PET/CT and DW-MRI to predict response to subsequent chemoradiotherapy in locally advanced HNSCC.
There are three main findings: first, the changes in FMI parameters measured by both modalities after IC1 are representative of its 'full' effect with few additional changes with IC2. This indicates that response assessment using 18 F-FDG-PET/CT and DWI-MRI at this early time-point is clinically relevant. To the best of our knowledge, this is the first study in HNSCC to provide full longitudinal 18 F-FDG-PET/CT and DW-MRI data following each cycle of IC.
Second, 18 F-FDG-PET/CT-derived MTV or TLG, acquired before and after IC1 are early predictors of response to subsequent chemoradiotherapy. The high predictive power achieved by a combination of these parameters enables early stratification of patients into distinct groups based on response and associated risk of subsequent chemoradiotherapy failure. This has important clinical applicability for guiding treatment personalisation. Patients with favorable metabolic response post-IC1 (reduction in MTV >55% or TLG >60%) could be considered for radiotherapy dose reduction, especially HPV-positive patients. On the contrary, those with unfavorable response should be considered for non-standard-chemoradiotherapy approach e.g. radiotherapy dose escalation, addition of novel targeted agents or surgery. IC should also be discontinued immediately in those with metabolic progression (increase in MTV or TLG). These preliminary findings provide the basis for a future interventional study using FMI parameters to stratify patients (Fig. 5) .
Third, residual MTV post-IC1 is a potential BTV for radiotherapy dose escalation. This is particularly relevant for those who had suboptimal metabolic response, where In contrast, we did not find pre-treatment ADC to be predictive of treatment outcome. A possible explanation for this is that a comparatively larger variation in pretreatment ADC, notably in the PT (range 0.9-1.54 x10 -3 mm 2 /s), was observed amongst We acknowledge the limitations of this study. A different PET/CT scanner was used for two patients, which may have influenced the reconstruction parameters. Four patients did not have measurable PT following diagnostic tonsillar biopsy or tonsillectomy. In addition, the cranio-caudal coverage of our MRI protocol (8 cm) meant that in three patients, involved LNs outside FOV were excluded from the analysis.
However, by including the largest nodal metastases, the dominant biology of the disease should have been captured.
CONCLUSION
Our unique longitudinal data demonstrates that early assessment after IC1 using FMI is clinically appropriate. In addition, 18 
